sb 202190 has been researched along with Glaucoma in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to explore the effects of SB 202190, a highly selective p38 MAPK inhibitor, on bleb survival following glaucoma filtering surgery." | 3.81 | A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery. ( Grisanti, S; Lüke, J; Lüke, M; Nassar, K; Tura, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nassar, K | 1 |
| Tura, A | 1 |
| Lüke, J | 1 |
| Lüke, M | 1 |
| Grisanti, S | 2 |
1 other study available for sb 202190 and Glaucoma
| Article | Year |
|---|---|
A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Enzyme Inhibito | 2015 |